Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Regenerative Medicine Groups in Asia Begin Discussions towards Mutual Approval
April 15, 2019
- JPMA Not Envisioning Asia-Version EMA at This Point: Chief
April 11, 2019
- Drug Damage Watchdog Nudges Govt, Shionogi to Suspend Xofluza Sales
April 10, 2019
- Vaccine Heavyweight Prods Japan to Expedite Recommendation Process for Immunization Program, Ensure Funding
April 9, 2019
- Patient Groups Press for Emergency Import of Methotrexate amid Tight Supply
April 8, 2019
- Hodanren Calls for Transparency in Kymriah Pricing Process
April 8, 2019
- No More Nonprescription Switches for Lifestyle Disease Drugs, Says JMA Exec
April 5, 2019
- Generic Use Rate at 74.7% in October-December 2018: JGA
March 29, 2019
- BMS Exec Ohura Appointed as CEO of GHIT Fund
March 29, 2019
- JPMA Poised to Continue Pitching Drugs’ Multi-Faceted Values to Politicians: Director General
March 25, 2019
- 2020 Drug Price Revision Is Focus Issue for FPMAJ in FY2019 Plan
March 25, 2019
- FPMAJ Wants Asian Equivalent of EMA, Chairman Stresses Merit of Blanket Approval
March 20, 2019
- EFPIA Official Prods Japan to Limit CEA Application to Financially Impactful Drugs
March 19, 2019
- Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
- Drug Damage Watchdog Opposes Legislation of Conditional Approval System, Calls for Tougher Rules on Ads
March 13, 2019
- Look at Societal Values of Medicines in Pricing: Japan Pharma Industry Chief
March 12, 2019
- Japan Has High Market Access Barriers, Revised PMP Could Stymie Innovation: US Chamber of Commerce Official
March 7, 2019
- Biotech Execs Raise Alarm over Price Maintenance Criteria, CEA Introduction: BIO Asia Confab
March 6, 2019
- Labor Groups Call for Careful Discussions on Cost Effectiveness Assessment
February 19, 2019
- EFPIA Japan Chief Says CEA Selection Criteria Mar Predictability, 5 Billion Yen Sales Threshold “Too Low”
February 19, 2019
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…